Research Article| Volume 51, ISSUE 4, P473-481, March 2015

Download started.


Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study

Published:January 27, 2015DOI:



      A dose-finding phase I/II trial that evaluated the maximum tolerated doses of a combination of three drugs with irinotecan, oxaliplatin and capecitabine (COI regimen) has been conducted in patients with metastatic colorectal cancer (mCRC). In this study the safety and activity of the combination of COI regimen plus bevacizumab (COI-B) were assessed.


      Patients judged to be unresectable for metastatic disease, were enrolled in a phase II, open-label study and treated with the combination of bevacizumab (5 mg/kg on day 1) and COI regimen (irinotecan 180 mg/mq on day 1, oxaliplatin 85 mg/mq on day 2, capecitabine 2000 mg d2–6; q14) as first-line treatment. Induction treatment was administered for a maximum of 8 cycles, followed by maintenance treatment with bevacizumab (7.5 mg/kg on d1, q21) until progression.


      Fifty-one patients were enrolled in six Italian centres. The primary end-point of overall response rate was met, reaching the value of 62% in the per-protocol population and 57% in the intent-to-treat population, patients with stable disease were also taken into account, the clinical benefit rate was 94%. In the intention-to-treat population, median progression-free and overall survivals were 10.3 and 22 months, respectively. Toxicity was different from 5-fluorouracil-based triplet regimens, with 31% of severe diarrhoea, but a low incidence of grade 3/4 neutropenia (6%) and mucositis (4%).


      Our results show the feasibility and promising activity of the combination of capecitabine, oxaliplatin, irinotecan and bevacizumab.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • American Cancer Society
        Cancer facts & figures 2014.
        American Cancer Society, Atlanta2014
        • Bengmark S.
        • Hafstrom L.
        The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy.
        Cancer. 1969; 23: 198-202
        • Grothey A.
        • Sargent D.
        • Goldberg R.M.
        • et al.
        Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
        J Clin Oncol. 2004; 22: 1209-1214
        • Tournigand C.
        • André T.
        • Achille E.
        • et al.
        FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
        J Clin Oncol. 2004; 22: 229-237
        • Guglielmi A.P.
        • Sobrero A.F.
        Second-line therapy for advanced colorectal cancer.
        Gastrointest Cancer Res. 2007; 1: 57-63
        • Falcone A.
        • Ricci S.
        • Brunetti I.
        • et al.
        Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
        J Clin Oncol. 2007; 25: 1670-1676
        • Souglakos J.
        • Androulakis N.
        • Syrigos K.
        • et al.
        FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).
        Br J Cancer. 2006; 94: 798-805
        • Bajetta E.
        • Celio L.
        • Ferrario E.
        • et al.
        Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
        Ann Oncol. 2007; 18: 1810-1816
      1. Bevacizumab summary of product characteristics. Available at: <> (last entry 09.04.14).

        • Masi G.
        • Loupakis F.
        • Salvatore L.
        • et al.
        Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
        Lancet Oncol. 2010; 11: 845-852
        • Therasse P.
        • Arbuck S.G.
        • Eisenhauer E.A.
        • et al.
        New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
        J Natl Cancer Inst. 2000; 92: 205-216
        • Di Bartolomeo M.
        • Pietrantonio F.
        • Perrone F.
        • et al.
        • on behalf of Italian Trials in Medical Oncology (ITMO) Group
        Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.
        Target Oncol. 2014; 9: 155-162
        • Molinari F.
        • Felicioni L.
        • Buscarino M.
        • et al.
        Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.
        Clin Cancer Res. 2011; 17: 4901-4914
      2. National cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) v. 3. Available at: <>.

        • Simon R.
        Optimal two-stage design for Phase II clinical trials.
        Control Clin Trials. 1989; 10: 1-10
        • Rubbia-Brandt L.
        • Giostra E.
        • Brezault C.
        • et al.
        Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
        Ann Oncol. 2007; 18: 299-304
        • Iacovelli R.
        • Pietrantonio F.
        • Palazzo A.
        • et al.
        Incidence and relative risk of grade 3 and 4 diarrhea in patients treated with capecitabine or 5-fluorouracil. A meta-analysis of published trials.
        Br J Clin Pharmacol. 2014; 24 ([Epub ahead of print])
        • Oostendorp L.J.
        • Stalmeier P.F.
        • Pasker-de Jong P.C.
        • et al.
        Review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer.
        Anticancer Drugs. 2010; 21: 749-758
        • Köhne C.H.
        • De Greve J.
        • Hartmann J.T.
        • et al.
        Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
        Ann Oncol. 2008; 19: 920-926
        • Fuchs C.S.
        • Marshall J.
        • Mitchell E.
        • et al.
        Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study.
        J Clin Oncol. 2007; 25: 4779-4786
        • Van Cutsem E.
        • Nordlinger B.
        • Cervantes A.
        • et al.
        • ESMO Guidelines Working Group
        Advanced colorectal cancer: ESMO clinical practice guidelines for treatment.
        Ann Oncol. 2010; 21: 93-97
        • Falvella F.S.
        • Cheli S.
        • Maggi C.
        • et al.
        Prospective observational study for DPYD and UGT1A1 deficiency-associated toxicity in patients with metastatic colorectal cancer (mCRC) receiving triplet chemotherapy with capecitabine, irinotecan and oxaliplatin (COI).
        Ann Oncol. 2014; 25 ([Abstr 532P])
        • Fischel J.L.
        • Rostagno P.
        • Formento P.
        • et al.
        Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.
        Br J Cancer. 2001; 84: 579-585
        • Gruenberger T.
        • Bridgewater J.A.
        • Chau I.
        • et al.
        Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: resectability and safety in OLIVIA.
        J Clin Oncol. 2013; 24 ([abstr 3619])
        • Loupakis F.
        • Cremolini C.
        • Salvatore L.
        • et al.
        FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
        Eur J Cancer. 2014; 50: 57-63
        • Loupakis F.
        • Cremolini C.
        • Masi G.
        • et al.
        Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
        N Engl J Med. 2014; 371: 1609-1618
        • Koeberle D.
        • Betticher D.C.
        • Von Moos R.
        • et al.
        Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III noninferiority trial (SAKK 41/06).
        J Clin Oncol. 2013; 31 ([abstr 3503])
        • Koopman M.
        • Simkens L.H.
        • May A.M.
        • et al.
        Final results and subgroup analyses of the phase 3 CAIRO3 study: maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC).
        J Clin Oncol. 2014; 32 ([abstr 3504])
        • Arnold D.
        • Graeven U.
        • Lerchenmuller C.A.
        • et al.
        Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): a phase III non-inferiority trial (AIO KRK 0207).
        J Clin Oncol. 2014; 32 ([abstr 3503])
        • Díaz-Rubio E.
        • Pietrantonio F.
        • de Braud F.
        Continuing single-agent bevacizumab as maintenance therapy after induction XELOX(or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer.
        Oncologist. 2012; 17: 1426-1428